1 Big Pharma Leaps Past Hurdle

Earlier this week, drugmaker Sanofi (NYSE: SNY  ) won approval for its multiple sclerosis treatment Lemtrada in the European Union. While the drug has yet to get the green light in the U.S., it is a key addition to Sanofi's multiple sclerosis lineup, which also includes the oral medication Aubagio. But can the company compete with Biogen (NASDAQ: BIIB  ) and its recently launched MS medication Tecfidera? Analysts David Williamson and Max Macaluso discuss this market in the following video.

9 rock-solid dividend stocks
One of the best parts of owning big pharma stocks is their attractive dividends, but smart investors know the importance of diversifying -- seeking high-yielding stocks from multiple industries. The Motley Fool's special free report "Secure Your Future With 9 Rock-Solid Dividend Stocks" outlines the Fool's favorite dependable dividend-paying stocks across all sectors. Grab your free copy by clicking here.

Editor's note: At 6:36, the speaker incorrectly states that Sanofi had a partnership with Rigel Pharmaceuticals. The Fool regrets the error.


Read/Post Comments (1) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On October 03, 2013, at 12:55 PM, ikkyu2 wrote:

    Lemtrada reduces disability, the only MS drug shown to do so, and requires only 6 infusions: 3 in one week at therapy start, 3 in one week at therapy end a year later.

    Initial profits from the drug will be diverted to paying dividends for a warrant called GCVRZ because Sanofi and Genzyme could not agree on the drug's value during the former's acquisition of the latter.

Add your comment.

DocumentId: 2645352, ~/Articles/ArticleHandler.aspx, 4/23/2014 12:38:51 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 16,490.35 -24.02 -0.15%
S&P 500 1,876.24 -3.31 -0.18%
NASD 4,134.29 -27.17 -0.65%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

4/23/2014 12:22 PM
SNY $53.15 Down -0.25 -0.46%
Sanofi (ADR) CAPS Rating: ****
BIIB $299.18 Down -7.02 -2.29%
Biogen Idec CAPS Rating: ****
REGN $304.44 Down -7.25 -2.32%
Regeneron Pharmace… CAPS Rating: **
RIGL $3.25 Down -0.17 -4.97%
Rigel Pharmaceutic… CAPS Rating: ***

Advertisement